A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

American Journal of Ophthalmology

Volumn 131, Issue 5, 2001, Pages 636-642

  Aung, Tin ^a   Chew, Paul T K ^a,b,e   Yip, Chee Chew ^c   Chan, Yiong Huak ^d   See, Jovina L S ^a   Khng, Christopher G ^a,c   Hoh, Sek Tien ^a,c   Ng, Lee Hwa ^d   Lee, Hung Ming ^c  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d National Medical Research Council   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; EYE IRRITATION; FEMALE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MODEL; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DINOPROST; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TREATMENT OUTCOME;

EID: 0035002436     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(00)00943-0     Document Type: Article

References (19)

1. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16.
2. Aim A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening and morning. A comparison with timolol. Ophthalmology 1995;102:1743-1752.
3. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103:138-147.
4. Watson P, Stjernschantz J, the Latanoprost Study Group. A six month randomized double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137.
5. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-939.
6. Camras CB, Alm A, Watson P, Stjernschantz J, the Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma treatment. Efficacy and safety after one year of treatment in 198 patients. Ophthalmology 1996;103:1916-1924.
7. Watson PG, the Latanoprost Study Group. Latanoprost - two years experience of its use in the United Kingdom. Ophthalmology 1998;105:82-87.
8. 2α analogue on aqueous humour dynamics in human eyes. Ophthalmology 1993;100:1297-1204.
9. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111: 1351-1358.
10. Azuma I, Masuda K, Kitazawa Y, et al. Double masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-525.
11. Azuma I, Masuda K, Kitazawa Y, et al. Long term study of UF-021 ophthalmic solution in patients with primary open angle glaucoma or ocular hypertension. Atarashii Ganka (J Eye) 1994;11:1435-1444.
12. Azuma I. Clinical evaluation of UF-021 ophthalmic solution in glaucoma patients refractory to maximum tolerable therapy. J Jpn Ophthalmol Soc 1993;97:232-238.
13. Taniguchi T, Haque MSR, Sugiyama K, et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug in rabbits. J Ocul Pharmacol 1996;12:489-498.
14. Taniguchi T, Sawada A, Sugiyama K, et al. Ocular hypotensive effects and mechanisms of prostaglandin-related drugs. Invest Ophthalmol Vis Sci 1997;38(Suppl.):815.
15. Serle JB, Podos SM, Kitazawa Y, Wang RF. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998;42:95-100.
16. Machin D, Campbell MJ, Fayers PM, Pinol A. Sample size tables for clinical studies. Oxford: Blackwell, 1997.
17. Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997;81:370-372.
18. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Ophthalmology 1998;105:263-268.
19. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126:37-41.